Clinical Trials Browser

Interventional × Fallopian Tube Neoplasms × tremelimumab × Clear all

NCT04034927 2026-04-13

Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer

Phase 2 Active not recruiting

61 enrolled 15 charts

Fallopian Tube Neoplasms

NCT03026062 2025-09-19

Durvalumab and Tremelimumab in Treating Participants With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Phase 2 Completed

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02571725 2025-05-23

PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer

Phase 1/2 Active not recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

NCT02953457 2024-11-19

Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation

Phase 2 Completed

40 enrolled 16 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02658214 2020-08-20

Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors

Phase 1 Completed

BreastGastrointestinalGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Peritoneal Neoplasms, Stomach Neoplasms, Carcinoma, Pancreatic Ductal, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms